ArticleBreast cancer : basic and clinical research2025
Memantine, an NMDA Receptor Antagonist, Attenuates Doxorubicin-Induced Cardiac Oxidative Stress and Inflammation in Mouse 4T1 Breast Cancer Model.
Article in Breast cancer : basic and clinical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting the nervous system: Mechanistic insights into neuro-tumor communication and therapeutic opportunities.Acta pharmaceutica Sinica. B · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Breast cancer is the most common cancer among women, and chemotherapy is a key treatment option. Doxorubicin is frequently used for breast cancer but poses a risk of cardiotoxicity. Recently, memantine, an N-Methyl-D-aspartate antagonist, has shown both antitumor and cardioprotective effects. Objectives: We conducted a study to examine the combined effects of doxorubicin and memantine on the 4T1 cell line in a breast cancer animal model and to assess memantine's potential in reducing doxorubicin-induced cardiotoxicity in breast cancer model mouse. Design: The 4T1 cell line was cultured and subsequently inoculated into mice. After that animals were randomly divided into four groups: (1) control, (2) memantine, (3) doxorubicin, and (4) memantine + doxorubicin. Methods: After 30 days, mice were sacrificed, and their lungs, liver, and heart were collected for histological analysis. Myeloperoxidase, Malondialdehyde, and TNF-α levels in cardiac tissues were measured, and the TUNEL test was conducted for breast tumors. Results: Our results showed that memantine + doxorubicin reduced MDA activity and TNF-α levels in cardiac tissue in comparison to the doxorubicin group. TUNEL test revealed that the memantine + doxorubicin group demonstrated significantly more tumor cell apoptosis than the mice in other groups ( Conclusion: This study is the first to demonstrate that memantine can enhance the therapeutic efficacy of doxorubicin chemotherapy while also reducing doxorubicin-induced cardiac oxidative stress and inflammation in a breast cancer model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.